Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II basket trial of IO102-IO103 plus pembrolizumab in first-line metastatic NSCLC, SCCHN, or urothelial bladder cancer
2021-003026-69Phase 2Active
- Sponsor
- IO Biotech
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of PD-L1/IDO peptide vaccine, pembrolizumab and montanide isa-51 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and transitional cell carcinoma (TCC) (3 cohorts), sponsored by IO Biotech. Primary endpoints: Objective response rate and Progression-free survival rate at 6 months. Started Dec 2021; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2021-003026-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003026-69.